Metagenomi furnishes Sep 2026 corporate presentation; deck details not in filing text

Metagenomi Therapeutics, Inc.

MGX issued a Sept 2026 corporate presentation positioning itself in precision gene editing for durable, curative medicines.
Filing text ends after company tagline; specific pipeline, financials, or partnerships were not reproduced in this extract.
Jian Irish, Ph.D., M.B.A. remains President and CEO per the 8-K signature block.
Company is an emerging growth company; shares trade on Nasdaq under ticker MGX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.